

## Publications ##

### Official ###

- Amundsen CL, Richter HE, Menefee S, Vasavada S, Rahn DD, Kenton K, Harvie HS, Wallace D, Meikle S. The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial. Contemporary clinical trials. **2014** Mar; 37(2): 272-83. PubMed: 24486637 PubMed Central: PMC3989885 NIHMS ID: NIHMS567329  
- Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT, Myers DL, Zyczynski HM, Vasavada S, Nolen TL, Wallace D, Meikle SF. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. JAMA. **2016** Oct; 316(13): 1366-1374. PubMed: 27701661 PubMed Central: PMC5399419 NIHMS ID: NIHMS854876  
- Amundsen CL, Richter HE, Wallace D, Pelvic Floor Disorders Network. OnabotulinumtoxinA vs Sacral Neuromodulation for Urgency Incontinence-Reply. JAMA. **2017** Feb; 317(5): 535-536. PubMed: 28170477 PubMed Central: PMC5534324 NIHMS ID: NIHMS871642  
- Richter HE, Amundsen CL, Erickson SW, Jelovsek JE, Komesu Y, Chermansky C, Harvie HS, Albo M, Myers D, Gregory WT, Wallace D, NICHD Pelvic Floor Disorders Network. Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence. The Journal of urology. **2017** 10; 198(4): 890-896. PubMed: 28501541 PubMed Central: PMC5599339 NIHMS ID: NIHMS892060
- Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, Vasavada SP, Nguyen JN, Wilson TS, Harvie HS, Wallace D, Pelvic Floor Disorders Network. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. Eur Urol. **2018** 07; 74(1): 66-73. PubMed: 29482936 PubMed Central: PMC6004242 NIHMS ID: NIHMS946024  
- Komesu YM, Amundsen CL, Richter HE, Erickson SW, Ackenbom MF, Andy UU, Sung VW, Albo M, Gregory WT, Paraiso MF, Wallace D, Eunice Kennedy Shriver National Institute of Child Health and Human Development Pelvic Floor Disorders Network. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications. American journal of obstetrics and gynecology. **2018** 01; 218(1): 111.e1-111.e9. PubMed: 29031894 PubMed Central: PMC5803754 NIHMS ID: NIHMS934672  
- Andy UU, Amundsen CL, Honeycutt E, Markland AD, Dunivan G, Dyer KY, Korbly NB, Bradley M, Vasavada S, Mazloomdoost D, Thomas S, NICHD Pelvic Floor Disorders Network. Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function. Am J Obstet Gynecol. **2019** 11; 221(5): 513.e1-513.e15. PubMed: 31211964 PubMed Central: PMC6911169 NIHMS ID: NIHMS1544836  
- Harvie HS, Amundsen CL, Neuwahl SJ, Honeycutt AA, Lukacz ES, Sung VW, Rogers RG, Ellington D, Ferrando CA, Chermansky CJ, Mazloomdoost D, Thomas S. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial. J. Urol.. **2020** 05; 203(5): 969-977. PubMed: 31738113 PubMed Central: PMC7204548 NIHMS ID: NIHMS1583176  
- Hendrickson WK, Xie G, Rahn DD, Amundsen CL, Hokanson JA, Bradley M, Smith AL, Sung VW, Visco AG, Luo S, Jelovsek JE. Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women. Neurourol Urodyn. **2022** Jan; 41(1): 432-447. PubMed: 34859485 NIHMS ID: 1760134  
- Gill BC, Thomas S, Barden L, Jelovsek JE, Meyer I, Chermansky C, Komesu YM, Menefee S, Myers D, Smith A, Mazloomdoost D, Amundsen CL. Intraoperative Predictors of Sacral Neuromodulation Implantation and Treatment Response: Results From the ROSETTA Trial. J Urol. **2023** Aug; 210(2): 331-340. PubMed: 37126070

### Official RUM ###

- Richter HE, Moalli P, Amundsen CL, Malykhina AP, Wallace D, Rogers R, Myers D, Paraiso M, Albo M, Shi H, Nolen T, Meikle S, Word RA, Pelvic Floor Disorders Network. Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls. The Journal of urology. **2017** 06; 197(6): 1487-1495. PubMed: 28089729 PubMed Central: PMC5433900 NIHMS ID: NIHMS843564

### Others ###


- Bickhaus, Jennifer A., Monique Vaughan, Tracy Truong, Yi-Ju Li, and Nazema Y. Siddiqui. “A Comparison of Antibiotic Prophylaxis Regimens to Decrease the Risk of Post-Procedure Urinary Tract Infection after Onabotulinum Toxin A Injection.” International Urogynecology Journal 31, no. 9 (September 2020): 1907–12. https://doi.org/10.1007/s00192-020-04230-7.
- Werneburg, Glenn T., Eric A. Werneburg, Howard B. Goldman, Andrew P. Mullhaupt, and Sandip P. Vasavada. “Neural Networks Outperform Expert Humans in Predicting Patient Impressions of Symptomatic Improvement Following Overactive Bladder Treatment.” International Urogynecology Journal, July 26, 2022. https://doi.org/10.1007/s00192-022-05291-6.

